Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free AVCT Stock Alerts

Avacta Group (AVCT) Competitors

Avacta Group logo
GBX 86.90 -2.10 (-2.36%)
As of 12:14 PM Eastern
Compare

AVCT vs. ONT, OXB, ERGO, SLN, and PRTC

Should you buy Avacta Group stock or one of its competitors? MarketBeat compares Avacta Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avacta Group include Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), and PureTech Health (PRTC). These companies are all part of the "biotechnology" industry.

How does Avacta Group compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Avacta Group has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£223.90M5.31-£175.21M-£15.10N/A
Avacta Group£113K3,487.58-£30.08M-£17.55N/A

In the previous week, Oxford Nanopore Technologies had 4 more articles in the media than Avacta Group. MarketBeat recorded 6 mentions for Oxford Nanopore Technologies and 2 mentions for Avacta Group. Oxford Nanopore Technologies' average media sentiment score of 1.24 beat Avacta Group's score of 0.10 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oxford Nanopore Technologies
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avacta Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

18.9% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 2.6% of Avacta Group shares are held by institutional investors. 2.3% of Oxford Nanopore Technologies shares are held by company insiders. Comparatively, 50.9% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oxford Nanopore Technologies presently has a consensus price target of GBX 218.60, suggesting a potential upside of 78.81%. Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 13.92%. Given Oxford Nanopore Technologies' higher probable upside, equities research analysts clearly believe Oxford Nanopore Technologies is more favorable than Avacta Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Oxford Nanopore Technologies has a beta of 0.869, meaning that its share price is 13% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Oxford Nanopore Technologies has a net margin of -64.85% compared to Avacta Group's net margin of -30,398.21%. Oxford Nanopore Technologies' return on equity of -29.43% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-64.85% -29.43% -14.42%
Avacta Group -30,398.21%-361.23%-21.80%

Summary

Oxford Nanopore Technologies beats Avacta Group on 10 of the 16 factors compared between the two stocks.

How does Avacta Group compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Avacta Group has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Biomedica£168.74M4.44-£143.51M-£26.92N/A
Avacta Group£113K3,487.58-£30.08M-£17.55N/A

Oxford Biomedica has a net margin of -17.85% compared to Avacta Group's net margin of -30,398.21%. Oxford Biomedica's return on equity of -48.56% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Biomedica-17.85% -48.56% -12.67%
Avacta Group -30,398.21%-361.23%-21.80%

Oxford Biomedica has a beta of 1.095, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

In the previous week, Avacta Group had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.67 beat Avacta Group's score of 0.10 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oxford Biomedica
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avacta Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oxford Biomedica currently has a consensus price target of GBX 687, indicating a potential upside of 10.99%. Avacta Group has a consensus price target of GBX 99, indicating a potential upside of 13.92%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Oxford Biomedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 2.6% of Avacta Group shares are owned by institutional investors. 25.9% of Oxford Biomedica shares are owned by company insiders. Comparatively, 50.9% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Avacta Group beats Oxford Biomedica on 9 of the 16 factors compared between the two stocks.

How does Avacta Group compare to Ergomed?

Ergomed (LON:ERGO) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Ergomed has a net margin of 9.87% compared to Avacta Group's net margin of -30,398.21%. Ergomed's return on equity of 18.08% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Ergomed9.87% 18.08% 10.16%
Avacta Group -30,398.21%-361.23%-21.80%

In the previous week, Avacta Group had 2 more articles in the media than Ergomed. MarketBeat recorded 2 mentions for Avacta Group and 0 mentions for Ergomed. Avacta Group's average media sentiment score of 0.10 beat Ergomed's score of 0.00 indicating that Avacta Group is being referred to more favorably in the news media.

Company Overall Sentiment
Ergomed Neutral
Avacta Group Neutral

Ergomed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

71.1% of Ergomed shares are held by institutional investors. Comparatively, 2.6% of Avacta Group shares are held by institutional investors. 18.2% of Ergomed shares are held by insiders. Comparatively, 50.9% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ergomed has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ergomed£152.09M0.00£15M£0.29N/A
Avacta Group£113K3,487.58-£30.08M-£17.55N/A

Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 13.92%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Ergomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ergomed
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Ergomed beats Avacta Group on 8 of the 15 factors compared between the two stocks.

How does Avacta Group compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

In the previous week, Avacta Group had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Avacta Group's average media sentiment score of 0.10 beat Silence Therapeutics' score of 0.00 indicating that Avacta Group is being referred to more favorably in the news media.

Company Overall Sentiment
Silence Therapeutics Neutral
Avacta Group Neutral

Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 13.92%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts plainly believe Avacta Group is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -30,398.21%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Silence TherapeuticsN/A N/A N/A
Avacta Group -30,398.21%-361.23%-21.80%

2.6% of Avacta Group shares are owned by institutional investors. 50.9% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Silence Therapeutics has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics£11.35M0.00N/A-£48.60N/A
Avacta Group£113K3,487.58-£30.08M-£17.55N/A

Summary

Avacta Group beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Avacta Group compare to PureTech Health?

Avacta Group (LON:AVCT) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

In the previous week, Avacta Group had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for PureTech Health. Avacta Group's average media sentiment score of 0.10 beat PureTech Health's score of 0.00 indicating that Avacta Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avacta Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PureTech Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.399308, meaning that its stock price is 40% more volatile than the broader market.

PureTech Health has a net margin of -2,355.32% compared to Avacta Group's net margin of -30,398.21%. PureTech Health's return on equity of -31.98% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Avacta Group-30,398.21% -361.23% -21.80%
PureTech Health -2,355.32%-31.98%-13.39%

Avacta Group currently has a consensus target price of GBX 99, suggesting a potential upside of 13.92%. PureTech Health has a consensus target price of GBX 508, suggesting a potential upside of 276.85%. Given PureTech Health's higher possible upside, analysts plainly believe PureTech Health is more favorable than Avacta Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Avacta Group has higher earnings, but lower revenue than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avacta Group£113K3,487.58-£30.08M-£17.55N/A
PureTech Health£4.66M70.43-£91.86M-£46.00N/A

2.6% of Avacta Group shares are held by institutional investors. Comparatively, 34.6% of PureTech Health shares are held by institutional investors. 50.9% of Avacta Group shares are held by company insiders. Comparatively, 13.4% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

PureTech Health beats Avacta Group on 8 of the 14 factors compared between the two stocks.

Get Avacta Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVCT vs. The Competition

Export
MetricAvacta GroupBiotechnology IndustryMedical SectorLON Exchange
Market Cap£394.10M£460.17M£6.29B£2.79B
Dividend Yield3.97%3.86%2.79%6.09%
P/E Ratio-4.953.7820.85366.15
Price / Sales3,487.587,812.86543.5788,429.84
Price / Cash15.0013.1342.9427.89
Price / Book5.9083.899.877.74
Net Income-£30.08M-£96.07M£3.55B£5.89B
7 Day Performance7.28%0.74%-0.23%0.82%
1 Month Performance20.69%0.80%1.47%2.78%
1 Year Performance148.29%70.32%41.05%87.90%

Avacta Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVCT
Avacta Group
1.6468 of 5 stars		GBX 86.90
-2.4%		GBX 99
+13.9%		+153.9%£394.10M£113KN/A120
ONT
Oxford Nanopore Technologies
2.649 of 5 stars		GBX 114.78
-2.4%		GBX 218.60
+90.4%		-11.6%£1.12B£223.90MN/A1,281
OXB
Oxford Biomedica
1.7431 of 5 stars		GBX 655.80
-0.5%		GBX 687
+4.8%		+115.8%£792.98M£168.74MN/A891
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35MN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AVCT) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners
One coin wired into Elon's vision
The SpaceX IPO is projected to raise $75 billion in a single day... When that happens, the insiders who cashed...
Crypto 101 Media | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Tengu is coming (prepare for June 16)
A data leak exposed the code name of an AI breakthrough called Project Tengu - and in just six days, it erased...
Chaikin Analytics | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel